C₉H₂₂NNaO₇P₂,H₂O

It is an aminobisphosphonate that, like other bisphosphonates, inhibits bone resorption. It is used to treat severe hypercalcemia and osteolytic bone lesions associated with malignant neoplasms and in the prevention and treatment of postmenopausal osteoporosis. It is administered by slow intravenous infusion every day or every 3 to 4 weeks depending on the disease.

At the date of last update we found no published data on its excretion in breast milk.

Most bisphosphonates are acidic compounds with low plasma concentrations. Both characteristics make it unlikely that they will be excreted in milk in clinically significant quantities.

Intestinal absorption of bisphosphonates is very low even on an empty stomach and is considered practically null in the presence of milk because they form unabsorbable compounds with calcium.

Expert authors consider probably compatible the use of this medication during breastfeeding ^{(Hale, Briggs 2015)}. Some authors recommend monitoring the infant's serum calcium levels during maternal treatment. ^{(Stathopoulos 2011)}

Until more data on this drug in relation to breastfeeding are known safer alternatives are preferable ^{(LactMed, French 2003, Siminoski 2000)}, especially in the neonatal period and in case of prematurity.

See below the information of these related products:

• Maternal Cancer; Maternal Neoplasia (Unsafe. Moderate/severe adverse effects. Compatible under certain circumstances. Follow-up recommended. Use safer alternative or discontinue breastfeeding from 5 to 7 T ½ . Read Commentary.)
• Maternal osteoporosis (Safe product and/or breastfeeding is the best option.)